SEC Form 10-Q filed by Vaxart Inc
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2024 | $4.00 | Outperform | Oppenheimer |
| 12/29/2021 | $13.00 → $12.00 | Buy | Jefferies |
| 11/2/2021 | $15.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/29/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/24/2021 | $13.00 | Buy | Jefferies |
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study - SOUTH SAN FRANCISCO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported additional positive data from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation constructs. Dr. Sean Tucker, Vaxart's Founder and Chief Scientific Officer, presented the data
Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes ATLANTA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.5 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today commented on what they consider to be misleading and potentially manipulative communications issued by the Company regarding its proposed reverse stock split at the special meeting of stockholder
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) ("Vaxart" or the "Company") announced today that its 2025 special meeting of stockholders (the "Special Meeting") has been adjourned to Friday, September 19, 2025 at 8:30 a.m. Pacific Time with respect to all proposals describe
Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00
Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00
8-K - Vaxart, Inc. (0000072444) (Filer)
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
- ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the senior management team will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025 at 4:30 p.m. ET / 1:30 p.m. PT. "Our leadership team is excited for this opportunity to connect with our stockholders directly. This fireside chat is a chance for
Reported positive topline data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently asked questions in advance of Special Meeting of Stockholders
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, August 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13755103 Investors may submit written questions in advance of the conference c
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025. "It has been a profound privilege to serve as Vaxart's Chairman and be a part of this incredible Company's journey for so many years," said Mr. Finney. "I am immensely proud of what w
- Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ
Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve
SC 13G/A - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)